Latest news with #Techniques
Business Insider
29-06-2025
- Business
- Business Insider
The new must-have for CEOs: An AI whisperer
A year ago, Glenn Hopper was advising just a handful of company leaders on how to embed AI agents and tools like ChatGPT throughout their organizations. Today, the Memphis-based AI strategist has an extensive waitlist of C-suite executives seeking his help with those tasks and more. "This technology is moving so fast, the gap between what CEOs need to know and what they actually understand is massive," said Hopper, a former finance chief and author of the 2024 book "AI Mastery for Finance Professionals: Foundations, Techniques, and Applications." That's why so many bosses are knocking on his door, he told Business Insider. Leadership coaches and consultants have long helped CEOs navigate the pressures of the corner office. Now, executive sherpas who were early to embrace AI say they're seeing a spike in CEOs seeking guidance on everything from vetting vendors and establishing safety protocols to preparing for the next big wave of AI breakthroughs. "Everything is inbound," said Conor Grennan, chief of AI Mindset, an AI consulting and training firm he founded in 2023. "We have a list a mile long." Grennan, also chief AI architect at New York University's Stern School of Business, said company leaders often reach out after struggling to get employees to adopt AI. They see other CEOs touting AI's benefits, and so they're feeling like they're behind, he said. 'It was garbage in, garbage out' Some of the AI gurus that company leaders are tapping helm (or work at) startups that were launched in recent years to take advantage of the AI boom. Others head up new or expanded AI teams within established advisory firms. Lan Guan was named Accenture's first chief AI officer in 2023, two decades after joining the professional-services firm. She's since been counseling a growing number of company leaders on how to bring AI into their organizations. "CEOs need an AI translator to basically sift through all this noise," she said. "The amount of signals you're getting, the amount of noise, it's so distracting." Company leaders are also seeking out AI gurus in some cases to fix mistakes they made while going at it alone. Guan recalled one CEO who came to her after the person's company had to pause a multi-million dollar investment in a custom AI model because employees trained it on dozens of different versions of the same operating procedure. "When they tried to scale, their data was not clean enough," she said. "It was garbage in, garbage out." Amos Susskind, CEO and founder of the London beauty-tech startup Noli, has been tapping Guan and members of her team for AI-related guidance for the past year. Noli's roughly 20 employees have been using AI tools to do their jobs and the company's beauty-product recommendation platform is powered by AI. "I'm in touch with AI leaders in Accenture probably five times a day," said Susskind, who previously led L'Oreal's consumer-products division for the U.K. and Ireland. Shaping the AI narrative leaders use Last year, 78% of workers said their organizations had used AI in at least one function, up from 55% in 2023, according to a March survey by global management consulting firm McKinsey. Companies are planning to dig into AI even more this year. A May survey from professional-services firm PricewaterhouseCoopers found that 88% of senior executives planned to increase their AI-related budgets in the next 12 months. "AI is in line with, if not bigger than, the internet," said Dan Priest, chief AI officer of PwC, whose position was created last year. Public company CEOs mentioned "agentic AI" — AI systems capable of acting autonomously — and similar terms on 269 conference calls in the second quarter, up from 12 during the same period last year, according to AI research firm AlphaSense. Getting those AI mentions right is another reason why company leaders are leaning on AI sages. CEOs need to consider more than just how investors and analysts interpret their remarks, said Priest. Employees are listening, too, and workplace experts say heightened anxiety among personnel can dent productivity and drive up turnover. "You want to be careful," warned Priest, who helps CEOs communicate their AI strategy externally. "The second you start talking about AI efficiencies, it makes your teams very nervous." CEOs also need to make sure employees using AI are doing so safely, said Hopper, the AI strategist in Memphis. "If you try to have too prohibitive a policy or don't have a policy at all, that's when people are going to do stupid stuff with data," he said. While CEOs may not want to be involved in every AI process or initiative happening at their companies, Hopper said the more hands-on experience they get with the technology, the better equipped they'll be to make smart decisions about how their organizations can benefit from it. Michael White, chief of MashTank, a boutique management consulting firm near Philadelphia, became one of Hopper's clients last year. Though he considers himself tech-savvy, White said Hopper got him up to speed on AI faster than he could've on his own. "We now have a bot that knows a lot of what I know, but has a better memory than I do," said White. Without an AI whisperer like Hopper, he added, "I'd still be at the starting gate."
Axios
17-06-2025
- Entertainment
- Axios
Chicago restaurants win three James Beard awards
Chicago restaurants including Oriole, Kumiko and Lem's Bar-B-Q won James Beard awards Monday night during a star-studded ceremony held at the Civic Opera House. Why it matters: The accolades can often bring in more business, tourism and tax revenue to a city that could use the extra dough. The big picture: The entire weekend of multiple Beard award ceremonies turned into celebrations of immigrants' contributions to American food culture at a time when they're under attack by the Trump administration. Outstanding Bar went to Julia Momosé, mixologist, chef and owner of the Japanese-inspired West Loop bar Kumiko. This was Momosé's second Beard after winning in 2022 for her book "The Way of the Cocktail: Japanese Traditions, Techniques, and Recipes." "This one is so much more special because it's about the whole team, current and past, and everyone who helped us even before we were open," Momosé tells Axios. "It's about our guests, our regulars, and those people who came in to give us a shot. It's such a beautiful community. And so this is just surreal." Best Chef Great Lakes went to Noah Sandoval of Oriole who sent a surrogate to accept and read his speech saying Sandoval is away, "focusing on improving and nurturing my mental health." The chef's message continued with words of respect to fellow nominees and push back to U.S. Immigration and Customs Enforcement. Between the lines: Gov. JB Pritzker and Mayor Brandon Johnson also used their time on stage to highlight Chicago and the contributions of its immigrants. Bottom line: Chicago may have been the biggest winner of the weekend as thousands of food lovers flocked to our town to eat, drink and enjoy beautiful spring days.
Business Wire
20-05-2025
- Health
- Business Wire
Clinical Trial Results Show Active Chest Tube Clearance as Part of an ERAS Program Significantly Improves Outcomes in Cardiac Surgery
IRVINE, Calif.--(BUSINESS WIRE)--ClearFlow, Inc., a medical device company based in Irvine, California, announced positive results from a clinical trial published in the peer-reviewed journal Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. The study, conducted by cardiac surgeons at Franciscan Health Indianapolis, is detailed in the article, ' Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization. ' The prospective trial evaluated ClearFlow's PleuraFlow Active Clearance Technology (ACT) System, which significantly reduced retained blood complications in heart surgery patients. The system minimized chest tube clogging, lowered the incidence of retained blood syndrome (RBS) and postoperative atrial fibrillation (POAF), as well as reduced median ICU hours during recovery. The PleuraFlow System, used at the bedside in the ICU, enables clinicians to maintain chest tube patency without compromising the sterile field. By ensuring effective evacuation of blood and fluid from the surgical site postoperatively, PleuraFlow reduces retained blood, a known contributor to complications such as POAF, pleural effusions, and pericardial effusions. Conducted from January 2020 to August 2023 at Franciscan Health Indianapolis, this pragmatic, prospective observational study included 1,334 adult cardiac surgery patients. The control group (650 patients) received standard drainage, while the intervention group (684 patients) received PleuraFlow's Active Tube Clearance. Key findings demonstrated for the patients receiving Active Tube Clearance include: 41% reduction in RBS (8.2% vs. 4.8%, p=0.014) 17% decrease in POAF (33.8% vs. 28.1%, p=0.049) 30% reduction in median ICU hours (51.6 vs. 36.3 hours, p<0.001) 64% reduction in ICU readmissions (3.2% vs. 1.17%, p=0.013) 23% decrease in total chest drainage (p<0.001), enabling earlier chest tube removal and faster recovery Principal investigator Marc Gerdisch, MD, Chief of Cardiovascular and Thoracic Surgery and Co-Director of the Heart Valve Center at Franciscan Health, stated, 'We studied the clinical outcomes and financial implications of PleuraFlow chest drains when added to our established ERAS Cardiac program protocols. The unequivocal positive results have led to significantly fewer complications, and hospital days. More recently, we have leveraged our confidence the chest is well drained to achieve a median time to extubation of zero hours. Perhaps most importantly, the bedside nurse is able to ensure the chest drain is patent.' Louis Perrault, MD, PhD, a study coauthor and cardiac surgeon at the Montreal Heart Institute, added, 'Conventional chest tubes are prone to clogging, which can hinder recovery. This study, alongside prior research, strongly supports incorporating PleuraFlow's active clearance into ERAS Cardiac Surgery programs to reduce RBS, POAF, and ICU time.' 'This study strengthens the evidence for PleuraFlow's role in improving patient outcomes,' said Hannah Beathard, CEO of ClearFlow. 'By maintaining chest tube patency, PleuraFlow reduces retained blood and related complications, aligning with the ERAS Cardiac Society's Class I, Level B-NR recommendation for active chest tube maintenance as a critical component of optimal cardiac surgery recovery.' About ClearFlow, Inc. ClearFlow, Inc. is an Irvine, CA based medical device company that has developed a patented active blood and fluid evacuation system to speed recovery, reduce complications and lower healthcare costs related to medical tube obstruction. The company has been awarded several prestigious awards, including the Global Frost & Sullivan Award for New Product Innovation, the European Association of Cardiothoracic Surgeons Techno-College Innovation Award for worldwide innovation that has the potential to change the standard of care in heart and lung surgery, and the Innovations in Cardiovascular Interventions Award, among others.
Yahoo
20-05-2025
- Health
- Yahoo
Clinical Trial Results Show Active Chest Tube Clearance as Part of an ERAS Program Significantly Improves Outcomes in Cardiac Surgery
Significant Reductions in Chest Tube Clogging, Complications, and Resource Use Demonstrated in Prospective Study IRVINE, Calif., May 20, 2025--(BUSINESS WIRE)--ClearFlow, Inc., a medical device company based in Irvine, California, announced positive results from a clinical trial published in the peer-reviewed journal Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. The study, conducted by cardiac surgeons at Franciscan Health Indianapolis, is detailed in the article, "Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization." The prospective trial evaluated ClearFlow's PleuraFlow Active Clearance Technology (ACT) System, which significantly reduced retained blood complications in heart surgery patients. The system minimized chest tube clogging, lowered the incidence of retained blood syndrome (RBS) and postoperative atrial fibrillation (POAF), as well as reduced median ICU hours during recovery. The PleuraFlow System, used at the bedside in the ICU, enables clinicians to maintain chest tube patency without compromising the sterile field. By ensuring effective evacuation of blood and fluid from the surgical site postoperatively, PleuraFlow reduces retained blood, a known contributor to complications such as POAF, pleural effusions, and pericardial effusions. Conducted from January 2020 to August 2023 at Franciscan Health Indianapolis, this pragmatic, prospective observational study included 1,334 adult cardiac surgery patients. The control group (650 patients) received standard drainage, while the intervention group (684 patients) received PleuraFlow's Active Tube Clearance. Key findings demonstrated for the patients receiving Active Tube Clearance include: 41% reduction in RBS (8.2% vs. 4.8%, p=0.014) 17% decrease in POAF (33.8% vs. 28.1%, p=0.049) 30% reduction in median ICU hours (51.6 vs. 36.3 hours, p<0.001) 64% reduction in ICU readmissions (3.2% vs. 1.17%, p=0.013) 23% decrease in total chest drainage (p<0.001), enabling earlier chest tube removal and faster recovery Principal investigator Marc Gerdisch, MD, Chief of Cardiovascular and Thoracic Surgery and Co-Director of the Heart Valve Center at Franciscan Health, stated, "We studied the clinical outcomes and financial implications of PleuraFlow chest drains when added to our established ERAS Cardiac program protocols. The unequivocal positive results have led to significantly fewer complications, and hospital days. More recently, we have leveraged our confidence the chest is well drained to achieve a median time to extubation of zero hours. Perhaps most importantly, the bedside nurse is able to ensure the chest drain is patent." Louis Perrault, MD, PhD, a study coauthor and cardiac surgeon at the Montreal Heart Institute, added, "Conventional chest tubes are prone to clogging, which can hinder recovery. This study, alongside prior research, strongly supports incorporating PleuraFlow's active clearance into ERAS Cardiac Surgery programs to reduce RBS, POAF, and ICU time." "This study strengthens the evidence for PleuraFlow's role in improving patient outcomes," said Hannah Beathard, CEO of ClearFlow. "By maintaining chest tube patency, PleuraFlow reduces retained blood and related complications, aligning with the ERAS Cardiac Society's Class I, Level B-NR recommendation for active chest tube maintenance as a critical component of optimal cardiac surgery recovery." About ClearFlow, Inc. ClearFlow, Inc. is an Irvine, CA based medical device company that has developed a patented active blood and fluid evacuation system to speed recovery, reduce complications and lower healthcare costs related to medical tube obstruction. The company has been awarded several prestigious awards, including the Global Frost & Sullivan Award for New Product Innovation, the European Association of Cardiothoracic Surgeons Techno-College Innovation Award for worldwide innovation that has the potential to change the standard of care in heart and lung surgery, and the Innovations in Cardiovascular Interventions Award, among others. PleuraFlow and Active Clearance Technology are registered trademarks of ClearFlow, Inc. View source version on Contacts Media Contact:Paul Williamspaul@ (310) 569-0023 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
